Company Overview and News


Add TRIL
to your dashboard

Headline News

Transformers And Rectifiers (India) Limited - Investor Presentation

2017-11-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Transformers And Rectifiers (India) Limited - Financial Result Updates

2017-11-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Transformers And Rectifiers (India) Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2017-11-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information. (15-0)

Trillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting

2015-12-03 marketwired
TORONTO, ONTARIO--(Marketwired - Dec. 3, 2015) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR) an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program targeting CD47 at the 57th Annual Meeting of the American Society of Hematology....

DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders

2015-11-29 finance.yahoo
DiaMedica Inc. , a clinical stage biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available, today announced ...

Avivagen Announces Two Appointments to Its Board of Directors, Mr. David Allan and Ms. Vanessa Grant

2015-11-29 finance.yahoo
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and ...

Trillium Therapeutics - A Compelling Investment At Current Levels

2015-05-18 seekingalpha
Celgene signs licensing agreement worth a potential $500M plus with Inhibrx for its anti-CD47 mAb (antibody).Trillium's patented anti-CD47 SIRPαFc fusion protein has shown preclinical advantages over

Healthcare ratings roundup - new coverage (part 1)

2015-05-15 seekingalpha
Five Prime Therapeutics (FPRX -0.7%) initiated with Outperform rating and $45 (114% upside) price target by Oppenheimer.Trillium Therapeutics (TRIL +9%) initiated with Outperform rating and $32 (60% u

Healthcare stock ratings: new coverage

2015-04-28 seekingalpha
Retrophin (RTRX) initiated with a Buy rating and $50 (120% upside) price target by Deutsche Bank.Stemline Therapeutics (STML -0.8%) initiated with Buy rating and $38 (146% upside) price target by H.C.

Trillium Therapeutics initiates equity offering

2015-03-30 seekingalpha
Trillium Therapeutics (NASDAQ:TRIL) commences a $50M public offering of common stock and preferred stock. The company is offering the common shares, including an underwriters over-allotment of 15% of

Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech

2015-02-13 seekingalpha
Essentially, each biotech stock is a special situation, and should be treated as such.The aging demographic is one factor driving the fertile market for new drugs.The FDA seems to have settled into a

Trillium Therapeutics up premarket

2014-12-31 seekingalpha
Recent IPO Trillium Therapeutics (NASDAQ:TRIL) is up 8% premarket on modest volume. The Toronto, Canada-based preclinical-stage firm develops cancer therapies. It began its corporate life in